Advertisement
JAGX vs MNOV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and MNOV is a StrongBuy.
Momentum Indicator for JAGX turns negative, indicating new downward trend
JAGX saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 67 similar instances where the indicator turned negative. In 65 of the 67 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for JAGX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for JAGX just turned positive on October 26, 2026. Looking at past instances where JAGX's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +10.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAGX advanced for three days, in 138 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
JAGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.070) is normal, around the industry mean (3.104). P/E Ratio (0.001) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.003) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. JAGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MNOV sees its Stochastic Oscillator climbs out of oversold territory
On October 28, 2026, the Stochastic Oscillator for MNOV moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 73 instances where the indicator left the oversold zone. In 55 of the 73 cases the stock moved higher in the following days. This puts the odds of a move higher at over 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Oscillator exited the oversold zone, 23 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on MNOV as a result. In 63 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for MNOV just turned positive on October 28, 2026. Looking at past instances where MNOV's MACD turned positive, the stock continued to rise in 35 of 53 cases over the following month. The odds of a continued upward trend are 66%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNOV advanced for three days, in 129 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
MNOV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MNOV crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MNOV entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.902) is normal, around the industry mean (3.104). P/E Ratio (-6.857) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. MNOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
JAGX | MNOV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 96 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 46 Fair valued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 98 | 58 | |
P/E GROWTH RATING 1..100 | 97 | 55 | |
SEASONALITY SCORE 1..100 | 35 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MNOV's Valuation (21) in the Biotechnology industry is in the same range as JAGX (46) in the Pharmaceuticals Generic industry. This means that MNOV’s stock grew similarly to JAGX’s over the last 12 months.
MNOV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that MNOV’s stock grew similarly to JAGX’s over the last 12 months.
MNOV's SMR Rating (96) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that MNOV’s stock grew similarly to JAGX’s over the last 12 months.
MNOV's Price Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for JAGX (98) in the Pharmaceuticals Generic industry. This means that MNOV’s stock grew somewhat faster than JAGX’s over the last 12 months.
MNOV's P/E Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for JAGX (97) in the Pharmaceuticals Generic industry. This means that MNOV’s stock grew somewhat faster than JAGX’s over the last 12 months.
| JAGX | MNOV | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 70% |
| Stochastic ODDS (%) | N/A | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 63% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 74% |
| Advances ODDS (%) | 20 days ago 80% | 7 days ago 67% |
| Declines ODDS (%) | 2 days ago 90% | 15 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 75% | N/A |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JAGX’s FA Score shows that 0 FA rating(s) are green while MNOV’s FA Score has 1 green FA rating(s).
- JAGX’s FA Score: 0 green, 5 red.
- MNOV’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JAGX’s TA Score shows that 3 TA indicator(s) are bullish while MNOV’s TA Score has 5 bullish TA indicator(s).
- JAGX’s TA Score: 3 bullish, 3 bearish.
- MNOV’s TA Score: 5 bullish, 4 bearish.
Price Growth
JAGX (@Biotechnology) experienced а -62.70% price change this week, while MNOV (@Biotechnology) price change was +2.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.94%. For the same industry, the average monthly price growth was -11.98%, and the average quarterly price growth was -17.06%.
Reported Earning Dates
JAGX is expected to report earnings on Nov 13, 2026.
MNOV is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
JAGX and
Correlation & Price change
A.I.dvisor indicates that over the last year, JAGX has been loosely correlated with VKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if JAGX jumps, then VKTX could also see price increases.
| Ticker / NAME | Correlation To JAGX | 1D Price Change % | ||
|---|---|---|---|---|
| JAGX | 100% | -45.43% | ||
| VKTX - JAGX | 45% Loosely correlated | -1.65% | ||
| FLNA - JAGX | 43% Loosely correlated | -9.81% | ||
| TCRT - JAGX | 36% Loosely correlated | -10.26% | ||
| MNOV - JAGX | 35% Loosely correlated | +2.86% | ||
| SPRO - JAGX | 33% Loosely correlated | -1.89% | ||
More | ||||